Furthermore, we identified Sal as a potential therapeutic agent for TNF-α inhibition, offering a broader perspective for the treatment of IBD and suggesting Sal as a promising candidate for the development of novel TNF-α inhibitors. This evidence concerns the gene TNF and inflammatory bowel disease.